Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.44 |
| ▸ | KDM5C | P41229 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17892448 | 0.90 | KDM4E (0.59) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL29699657 | 0.88 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL820141 | 0.88 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL17892403 | 0.87 | SORT1 (0.48) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL293611 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL5834949 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL293610 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL28051316 | 0.80 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10GAAMAPT | |
| SCHEMBL15762092 | 0.79 | CYP46A1 (0.50) | KDM4EALDH1A1HPGDHSD17B10ATM | |
| SCHEMBL1018113 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | KDM4E 916/4885ALDH1A1 3567/4885HPGD 3385/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | KDM4E 916/4885ALDH1A1 3567/4885HPGD 3385/4885 |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | BTK, SYK, ABL1 | KDM4E 806/4885ALDH1A1 745/4885HPGD 3494/4885 |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | KDM4E 806/4885ALDH1A1 745/4885HPGD 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.